Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (KURA)
NASDAQ:KURA
Kura Oncology (KURA) Stock Price & Analysis
477 Followers
KURA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$7.41 - $24.17
Previous Close$20.95
Volume532.02K
Average Volume (3M)714.47K
Market Cap
$1.60B
Enterprise Value$1.09B
Total Cash (Recent Filing)$527.12M
Total Debt (Recent Filing)$16.97M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Aug 01, 2024EPS Estimate
-$0.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding76,180,620
10 Day Avg. Volume787,498
30 Day Avg. Volume714,470
Standard Deviation0.18
R-Squared0.08
Alpha0.00619
Financial Highlights & Ratios
Price to Book (P/B)4.02
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.47
Forecast
1Y Price Target
$30.63Price Target Upside46.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Kura Oncology News
PremiumCompany Announcements
Kura Oncology Enhances Equity Plan and Elects Directors
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressKura's menin inhibitor ziftomenib shows impressive progress, indicating a transformative year ahead with its potential as a best-in-class therapy for leukemia.
Financial StabilityKura Oncology's robust cash position, with a financial runway extending into 2027, ensures the company's stability and supports ongoing research and development.
Trial Enrollment And InterestThe rapid completion of Kura’s AML treatment trial enrollment demonstrates strong interest and momentum, suggesting a promising future for the drug.
Bears Say
Clinical TrialsPotential risks include failed clinical trials which could affect the company's ability to continue drug development.
Financial PerformanceKura reported no revenue with R&D and SG&A expenses higher than estimates.
RevenueKura reported no revenue for a recent quarter.
---
Ownership Overview
7.49% Insiders
15.87% Mutual Funds
15.82% Other Institutional Investors
60.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
KURA FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was $7.41 and its highest was $24.17 in the past 12 months.
What is Kura Oncology’s market cap?
Currently, no data Available
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Aug 01, 2024 which is in 10 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on May 02, 2024. The company reported -$0.59 earnings per share for the quarter, missing the consensus estimate of -$0.547 by -$0.043.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -$0.63.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 76,180,620 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -$0.59 in its last earnings report, missing expectations of -$0.547. Following the earnings report the stock price went up 0.194%.
Which hedge fund is a major shareholder of Kura Oncology?
Among the largest hedge funds holding Kura Oncology’s share is Deerfield Management Company, LP. It holds Kura Oncology’s shares valued at 115M.
---
Kura Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.63 (46.21% Upside)
$30.63 (46.21% Upside)
Blogger Sentiment
Bullish
KURA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 204.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
89.76%
12-Months-Change
Fundamentals
Return on Equity
-37.34%
Trailing 12-Months
Asset Growth
30.03%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.
---
KURA Company Deck
---
KURA Earnings Call
Q1 2024
0:00 / 0:00
---
KURA Stock 12 Month Forecast
Average Price Target
$30.63
▲(46.21% Upside)
Technical Analysis
Best Analysts Covering KURA
1 Year
1 Year Success Rate
12/15 ratings generated profit
1 Year Average Return
+58.02%
reiterated a buy rating 28 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +58.02% per trade.
---